Research at Karmanos Cancer Institute

As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are not available anywhere else. More than $60 million is invested each year into cancer research with a level of commitment and expertise that cannot be duplicated at community hospitals. 

Maximally Effective Treatment

We believe that our total focus on cancer ensures we will always be the best in developing and applying maximally effective treatment options. Our energy and resources are never diverted to other pursuits.

Learn more about research at Karmanos

    Types of Research

    A cornerstone of the Institute's cancer investigations, tracing its roots back to the establishment of the Detroit Institute for Cancer Research in 1943. Achievements include establishing the first immortal hormone dependent breast cancer cell line, MCF-7, and establishment of premalignant cell line MCF-10; and synthesis of AZT, ddC and d4T, the first FDA-approved treatments for AIDS.

    Clinical research

    Conducted through more than 800 clinical trials at the Institute, including one of the country's leading Phase I programs. Studies are institutional (designed/led by our own investigators), cooperative (with such groups as the Southwest Oncology Group), and pharmaceutical/industry trials. Achievements include establishing the international, nonsurgical standard therapy for anal and esophageal cancers and the concept of the multidisciplinary team, organ preservation and adjuvant chemotherapy.

    Population Research

    • Epidemiological research - Provides a quantitative portrait of cancer and its determinants in a defined population. Core functions are measurement of cancer incidence, morbidity, survival, and mortality. This also includes assessing of genetic predisposition, environmental and behavioral risk factors, screening practices, and the quality of care: from prevention through rehabilitation or hospice.
    • Behavioral research - Investigates whether racial and ethnic attitudes and biases, and real or perceived cultural differences among minority group patients impede effective communication and decision-making in doctor-patient interactions. 

    Karmanos Grand Rounds

    The principal objective of the Karmanos Grand Rounds is to update cancer researchers and physicians on recent advances in the prevention, detection and treatment of cancer.

    View upcoming presentations

The Latest From Karmanos Cancer Institute

News

Karmanos Cancer Institute Receives the Women’s Choice Award® as one of America’s Best Hospitals for Cancer Care for 10th consecutive year

For the 10 th consecutive year, the Barbara Ann Karmanos Cancer Institute has been named one of America’s Best Hospitals for Cancer Care by the Wo...

Read More

IN THE NEWS: Even in the fight of her life, selflessness wins out

517 Business and Lifestyle Magazine It started with cookies for the staff at Karmanos Cancer Institute at McLaren Greater Lansing . Now, Jamie Hut...

Read More

Collaborative Karmanos, Wayne State and Duke University research teams identify gene mutation in Black men that causes early prostate cancer

Researchers at Barbara Ann Karmanos Cancer Institute and Wayne State University have recently found inherited genetic variants mostly involved in ...

Read More
News

ASCO Education – Impact of Implicit Racial Bias on Oncology Patient Care and Outcomes

Listen Now

OncLive On Air - Dr. Cole Shares Insights on Culturally Relevant Myeloma Care

Listen Now

OncLive On Air - Dr. Deol on the Importance of a Well-Rounded Fellowship Experience

Listen Now